Introduction
============

Disturbed sleep belongs to the major complaints of pain patients ([@B86]; [@B24]; [@B58]). Clinical and experimental studies have shown that sleep deprivation is able to substantially aggravate the pain condition of pain patients ([@B42]; [@B83]; [@B82]). Even more, sleep disturbances and pain are considered to be mutually reinforcing, thus leading to a vicious cycle ([@B8]; [@B73]). Though being clinically highly relevant, the neurobiological mechanisms underlying the pro-nociceptive effects of disturbed sleep are barely known. Beyond its impact on pain, disturbed sleep is also known to deteriorate the affective state of pain patients. Namely, the anxiogenic effect of disturbed sleep is well acknowledged ([@B71]; [@B6]; [@B64]; [@B27]). Only recently, the anxiogenic effect of sleep deprivation has been shown to be correlated with brain morphology changes in the ventromedial prefrontal cortex and -- in women -- with reduced gray matter volume in the anterior insula and lateral orbitofrontal cortex ([@B27]). Part of these cortical areas -- like the insula and the ventromedial prefrontal cortex -- do not only belong to the affective-motivational dimension of pain processing ([@B62]; [@B5]; [@B55]; [@B41]) but are also target regions of the neurohypophysial hormone oxytocin (OT) ([@B70]; [@B67]). This neuropeptide, being largely recognized for its role in social behavior ([@B56]; [@B48]; [@B85]) and its modulatory effects on anxiety ([@B47]; [@B57]), has recently gained considerable attention with respect to its involvement in nociceptive processing ([@B29]; [@B10]; [@B26]; [@B93]). Several kinds of mechanisms have been described by which OT may contribute to the modulation of nociceptive processing. Supraspinally, extrahypothalamic projections of OT neurons to limbic brain regions, like the anterior cingulate cortex and amygdala, suggest a role of OT for the affective dimension of pain processing ([@B40]; [@B32]). At the brainstem level, anatomical ([@B14]; [@B44]) and functional ([@B94]) data indicate that OT is involved in descending pain modulation of the PAG-RVM (periaqueductal gray -- rostral ventromedial medulla) pathway, where it interacts with the opioidergic system. Via hypothalamo-spinal projections to dorsal horn neurons, OT is involved in nociceptive processing at the spinal cord level ([@B76]; [@B18]). Only recently, a peripheral mode of action was proposed according to which OT may interact with nociceptive-specific nerve terminals in the skin ([@B28]).

During the last decade, the anti-nociceptive potency of OT has been intensively studied. Surprisingly, while preclinical evidence strongly points to a considerable role of OT in pain-related behavior, results from human studies are highly equivocal. Like recently summarized, only about half of the previous human studies on the involvement of OT in nociception were able to confirm anti-nociceptive effects of OT, while the remaining studies failed to convincingly demonstrate a pain modulating role. Differences between methodological approaches to explore the role of OT (exogenous application versus assessment of endogenous levels) and between outcome measures (spontaneous pain versus evoked pain) may particularly contribute to the large heterogeneity of study results \[see ([@B65]; [@B87]; [@B10]; [@B93]) for review\].

Compared to the field of pain research, little is known about the contribution of the OT-system for the physiology and pathophysiology of sleep. Only chronobiological aspects have been addressed, indicating that the OT-system is not subject to circadian variations ([@B4]; [@B9]). We aimed to explore the neurobiological correlates underlying sleep deprivation induced changes of pain sensitivity and state anxiety. Backed by current knowledge, we hypothesized a pathophysiological role of OT for both the deterioration of pain and the affective state of sleep deprived individuals. To address this topic, a well-established human experimental model of one-night total sleep deprivation (TSD) was used. This model has been shown to increase the sensitivity to noxious stimuli ([@B43]; [@B34]; [@B78]; [@B22]) \[see ([@B77]) for review\] and to be anxiogenic ([@B78]; [@B79]; [@B22]). We hypothesized (1) a significant impact of sleep deprivation on the activity of the OT-system and, hence, on OT-release into the blood circulation and (2) a significant correlation between the concentration of plasma OT and TSD-induced alterations of evoked pain and anxiety. Since the involvement of OT in social and anxiety-related behavior is highly gender-specific ([@B49]; [@B20]; [@B68]; [@B75]; [@B87]; [@B46]; [@B11]), the role of sex was explicitly respected in our study. Therefore, a highly homogenous sex-mixed study population (*n* = 10 females and *n* = 10 males) was investigated. All females took monophasic oral contraceptives OC (see details below) and were strictly investigated during their "pill-free" phase. The effect of TSD on the nociceptive system was assessed by (1) using a QST battery ([@B69]) and (2) a "Cold Pressor Test," which enables to estimate the individual's capacity to inhibit pain ([@B95]; [@B96]). The impact of TSD on anxiety was evaluated by using the State-Anxiety Inventory ([@B84]). Finally, the salivary concentration of cortisol as a flanking biomarker for the stress-level of our study subjects was determined.

Materials and Methods {#s1}
=====================

This study was carried out in accordance with the Declaration of Helsinki and in accordance with the recommendations of the Local Ethical Committee of the Medical Faculty of Mannheim. The protocol was approved by the Local Ethical Committee of the Medical Faculty of Mannheim. All subjects gave written informed consent prior to study enrollment in accordance with the Declaration of Helsinki.

Subjects
--------

The study was performed in a subset of the previously described study population of *n* = 36 study participants ([@B22]) and comprised ten young healthy female (age 24.0 ± 2.7, mean ± SD; range 22--30 years) and male (23.4 ± 1.8; range 22--26 years) students. Somatic or psychiatric diseases and, in particular, pain disorders or insomnia were excluded in all study participants by taking their medical history, performing a physical and neurological examination and by using psychological questionnaires BDI ([@B7]), STAI-Trait Inventory ([@B84]). Both BDI-scores (females: 0.2 ± 0.7 and males: 1.0 ± 1.5, mean ± SD) and Trait Anxiety Scores (females: 28.1 ± 5.1 and males: 27.6 ± 4.2, mean ± SD) were within normal limits and did not indicate depression or anxiety. Primary pain or headache disorders were excluded as well as any serious pain-associated physical trauma. The ICHD-II classification criteria ([@B36]) were used to explicitly exclude patients with a diagnosis of migraine \[1.1, 1.2\] or probable migraine \[1.6\]. Importantly, females complaining of a peri-menstrual syndrome were excluded from the study. Sleep histories were taken from all study participants and the PSQI ([@B13]) (range: 0--21; scores \< 5: good sleepers without clinical signs of insomnia) was used to quantitatively assess their individual sleep quality. According to our results (PSQI: females: 1.4 ± 1.1 and males: 1.8 ± 1.1, mean ± SD), none of the study participants suffered from sleep disturbances. A lark and owl questionnaire ([@B90]) was used to determine sleep preferences and to exclude extreme morning (score ≥ 70) or extreme evening types (score ≤ 30). Results from this questionnaire indicated that all but two study participants belonged to the "neutral type" (females: 51.4 ± 3.7 and males: 50.3 ± 6.3, range 43--59) with two males ranging at the border to the "moderate evening type" (Score: 59). Demographic data are shown in **Table [1](#T1){ref-type="table"}**.

###### 

Demographic data.

  No.   BDI   STAI-trait   PSQI   Lark/Owl
  ----- ----- ------------ ------ ----------
  1     0     22           1      54
  2     0     26           1      55
  3     0     27           0      51
  4     0     35           3      43
  5     0     22           1      55
  6     0     37           3      49
  7     2     28           1      53
  8     0     28           1      51
  9     0     28           1      52
  10    2     32           1      51
  11    0     27           3      52
  12    2     30           1      50
  13    2     25           1      59
  14    4     26           4      50
  15    0     28           2      42
  16    0     21           1      46
  17    0     36           1      44
  18    1     30           1      44
  19    0     25           2      59
  20    0     33           4      52
                                  

BDI, beck depression inventory (range 0--20); STAI-Trait, trait scores of the state and trait anxiety inventory (range 20--80); PSQI, Pittsburgh sleep quality index (range 0--21); Lark/Owl, Lark/Owl questionnaire (range 16--86; 16--30: extreme evening type; 31--41: moderately evening type, 42--58: neutral type; 59--69: moderately morning type; 70--86: extreme morning type).

None of the study participants took analgesics. All study participants were non-smokers. They were asked to abstain from caffeine or any caffeinated beverages at least three days before the experiment took place. Since estrogens are known to impact on OT synthesis and release ([@B61]; [@B91]; [@B17]; [@B49]), it was important to study all female subjects in the same phase of their menstrual cycle and -- since contraceptives are also known to impact on OT ([@B80]; [@B16]; [@B72]; [@B74]) -- to use a homogenous female study population with respect to contraceptives. This condition was fulfilled by the fact that all female study participants were on monophasic contraceptives. In nine of ten females, the concentration of ethinylestradiol was 0.03 mg per tablet, while the contraceptive pill of one female contained 0.02 mg ethinylestradiol per tablet. All females were exclusively studied during their "pill pause" (day 3 to 7). In seven of the ten female subjects, the experiments were performed at exactly the same day of their menstrual cycle.

Study Protocol
--------------

All study subjects filled in sleep diaries at least five days before experiments took place. To objectively monitor their sleep-wake cycles, participants were asked to carry a commercially available battery-operated piezoelectric device (Actiwatch^®^ Device, Philips Respironics, Amsterdam) around the wrist. Continuous motion data, recorded by this Actiwatch Device, are translated into periods of 'activity' and periods of 'rest' by using the Respironics Actiwatch Software (Respironics Actiware^®^ Version 5.59.0015) \[see ([@B78]) for details\]. We used a balanced cross-over design with the same number of participants (*n* = 5 for each gender), either starting with a night of habitual sleep (HS) or a night of TSD. The time-interval between the two study experiments was adjusted to the female cycle. To avoid biasing due to alternation of the sleep-wake rhythm from weekend to weekday, experiments never took place on Mondays.

For the condition "HS," study participants were allowed to spend the night at home to avoid artificial surroundings which may have influenced their sleep quality. The night of TSD was spent at our Institute, where a medical student played games and chatted with the study participants to keep him/her continuously active. For double-check, participants had to keep wearing the Actiwatch device also during the sleep deprivation night.

Analysis of Actiwatch data revealed an average total sleep time on weekdays of 7.3 ± 0.4 and 8.8 ± 0.6 h at weekends. As expected, the total sleep time at the sleep deprivation night was 0 ± 0 h.

Study Schedule
--------------

Experiments started at eight o'clock in the morning. After a drug screening test (Drug-Screen, nal von minden GmbH, Germany) and before serving breakfast, saliva (cortisol) and blood samples (OT) were collected. All participants ate a standard breakfast (white bread, butter, honey, fruit, or herbal tea). Thereafter, subjects had to fill in the State-Anxiety Inventory of the STAI. As a next step, QST was performed on the non-dominant hand to determine the effect of TSD on nociception (duration: 30 min). Upon completion of QST, a cold pressor test was performed (see below).

Outcome Measures
----------------

### Quantitative Sensory Testing (QST)

To explore the effect of TSD on pain sensitivity, a QST procedure, developed by the German Research Network on Neuropathic Pain (DFNS), was used. A detailed description on testing procedures and quantitative assessment has been formerly published ([@B78]; [@B22]). The following description is restricted to the assessment of nociceptive thresholds, since the presented study only relates to these parameters. We used the TSA II NeuroSensoryAnalyzer (MEDOC, Israel) to assess the effect of TSD on thermal pain thresholds. Temperature changes were run in ramps of 1°C/s with a low cut-off of 0°C and a high cut-off of 50°C. Starting from a baseline-temperature of 32°C, the temperature of the thermode (surface: 9 cm^2^) was decreased/increased three times and the subjects were asked to press a PC mouse button as soon as they perceived a change from the impression of a warm/cold sensation toward an additional impression of a "burning," "stinging," "drilling," or "aching" sensation. The arithmetical mean of three measurements was calculated to determine CPT and HPT. For measuring MPTs of pricking forces, pinprick devices with a flat contact area of 0.25 mm diameter, ranging from 8 to 512 mN (MRC systems, Heidelberg, Germany), were used. Pinprick devices were applied in five series of ascending and descending stimulus intensities. MPT was then determined by calculating the geometric mean of the 5 series of ascending and descending stimulus intensities. A pressure algometer (Wagner Instruments, Greenwich-CT, probe diameter 1.0 cm^2^, up to 2000 kPa pressure) was applied on the thenar eminence with a pressure ramp of 50 kPa/s. The arithmetical mean of three measurements was then calculated to determine the PPT.

For details of the instruction, see <http://www.neuro.med.tu-muenchen.de/dfns/pdfs/QST-Investigators_brochure_Version_2_1_final_english_2010_07_09.pdf>.

### Assessment of Descending Pain Inhibition: "Cold Pressor Test"

To determine the individual's capacity to inhibit pain, the impact of ice cold water -- serving as conditioning stimulus -- on PPTs was assessed ([@B95]; [@B96]). PPT was determined by applying the same pressure algometer already used for QST (see above). Study participants were instructed to immerse their dominant hand up to ∼12 cm of the distal forearm into a tank filled with ice-cold water with their fingers spread apart. The temperature (0--2°C) was measured by a calibrated mercury thermometer (0--100°C). Subjects were instructed to pull their hand out of the water as soon as the painful sensation became intolerable with a predetermined maximum exposition time of 180 s. The impact of the conditioning stimulus (ice cold water) on the test stimulus (PPT) was assessed by subtracting PPT~post~ from PPT~prae~ (=PPT~prae-post~).

To correlate plasma OT levels with the individual endogenous capacity to inhibit pain, a ratio between PPT~prae-post~ (TSD) and PPT~prae-post~ (HS) was calculated (=Ratio PPT~prae-post~). By doing so, a value \>1.0 indicated that the conditioning stimulus (ice cold water) resulted in an increased capacity to inhibit pain, while values \<1.0 indicated a change toward pain facilitation.

### Blood/Saliva Sampling and Hormone Analysis

#### Blood samples

We used 5 ml of EDTA blood for the assessment of plasma OT concentrations. After venous puncture, the 5 ml EDTA vacutainer tubes were immediately cooled in ice-chilled water at 4°C. The samples were then centrifuged at 4°C at 4000 rpm for 5 min, aliquoted and stored at -20°C. After completion of the study, plasma samples were sent on dry ice to Munich, Germany. After extraction using LiChroprep Si60 (Merck), the samples were analyzed using a sensitive radioimmunoassay (RIAgnosis, Munich, Germany; see ([@B51]). The assay detection limit was 0.1 pg/sample, and cross-reactivity with other related neuropeptides was \<0.7%. The coefficient of variation for intra-assay precision was \<8%, whereas inter-assay variation was eliminated by measuring all samples within the same assay.

#### Saliva

Saliva was collected by using cortisol salivettes with a synthetic swab (Reg. Nr. 51.1534.500, Sarstedt Company, Nümbrecht, Germany). The saliva samples were stored at -20°C until shipping to the Biochemical Laboratory, Trier University, Germany, where the samples were analyzed. Saliva samples were centrifuged at 2000 *g* for 10 min. 100 ul of saliva were used for duplicate analysis. Cortisol levels were determined employing a competitive solid phase time-resolved fluorescence immunoassay with flouromeric end point detection (DELFIA). Standards, controls (saliva pools) and samples were given in duplicate wells. Cortisol concentrations of the samples were calculated with VICTOR X4^TM^ Multilabel Plate Reader (Perkin Elmer, MA, United States). The intra-assay coefficient of variation was between 4.0 and 6.7%. Inter-assay variation was eliminated by measuring all samples within the same assay \[see ([@B19])\].

Statistical Analysis
--------------------

We used RM-ANOVA analyses \[within subject's factor: "sleep" (HS or TSD), between subject's factor: sex\] to determine the impact of sleep deprivation on the outcome parameters. Prior to statistical analysis, the QST parameters PPT and MPT had to be transformed logarithmically in order to achieve normal distribution ([@B69]). For direct comparison of outcome parameters under the two conditions HS and TSD, paired *t*-tests were additionally performed.

To determine the overall relation between OT levels and the respective outcome parameters, linear regression analyses were performed. Thereafter, a hierarchical model of analysis was applied to specifically evaluate the contribution of "sex" and of "sleep" (HS versus TSD) on our results. Therefore, the respective dependent variable of interest was first entered to the model and "OT" was determined as an independent variable (step 1). Thereafter, "sex" (step 2) and "sleep" (step 3) were added to the model.

Statistics were done using the software package IBM SPSS Statistics 20. The significance level was set to α ≤ 0.05. Cohen's d and partial eta squared were used as the measure for effect size.

All data passed tests for normality (Normality test Shapiro--Wilk) and homogeneity of variance. Mauchley's Test of Sphericity, applied in RM-ANOVA analyses, was in no case violated.

Results
=======

Effect of TSD on OT
-------------------

According to RM-ANOVA, there was a significant main effect for OT regarding sex (*p* = 0.002) and a significant interaction between the sleep condition (HS versus TSD) and sex (*p* = 0.026). "Sleep" condition as a main factor just failed to have a significant effect on OT levels (*p* = 0.057). Separate analyses on the effect of TSD on OT-levels in females and males revealed a 58.9 ± 40.5% increase in females (*p* = 0.02), while plasma OT levels of males remained unchanged or even tended to decrease (8.7 ± 16.6 decrease; *p* = 0.34) (see **Figure [1](#F1){ref-type="fig"}** and **Table [2](#T2){ref-type="table"}**).

![Effect of sleep deprivation on plasma oxytocin and cortisol. **(A)** We found a significant effect of TSD on oxytocin levels in females (left), but not males (right). **(B)** Based on the entire study population, TSD just failed to change oxytocin levels (*p* = 0.057). ^∗^*p* \< 0.05; data are given as mean ± SEM.](fnbeh-12-00161-g001){#F1}

###### 

RM-ANOVA.

                   Sleep         Sex      Sleep ^∗^ sex                                                
  ---------------- ------------- -------- --------------- ----------- -------- ------- ------- ------- -------
  Oxytocin         0.057         4.134    0.187           0.002       13.164   0.422   0.026   5.874   0.246
  Cortisol         0.241         1.470    0.075           **0.048**   4.508    0.200   0.273   1.279   0.066
  CPT              **0.050**     3.470    0.162           0.763       0.094    0.005   0.584   0.311   0.017
  HPT              **0.023**     6.221    0.257           0.257       1.368    0.071   0.036   5.155   0.223
  Log MPT          **0.013**     7.564    0.296           0.646       0.219    0.012   0.040   4.896   0.214
  Log PPT          0.119         2.676    0.129           **0.020**   6.524    0.266   0.748   0.106   0.006
  PPT~prae-post~   0.739         0.115    0.006           0.812       0.058    0.003   0.013   7.533   0.295
  State anxiety    **\<0.001**   23.984   0.571           0.740       0.113    0.006   0.429   0.653   0.035
                                                                                                       

RM-ANOVA: within subjects factor: sleep (HS vs. TSD), between subjects factor: sex

η

p

2

: partial eta squared. Sleep

∗

sex: interaction between Sleep and sex. Values marked in bold indicate significancy of results.

Effect of TSD on Cortisol
-------------------------

We found a main effect of sex on saliva cortisol levels (*p* = 0.048, *F* = 4.508; **Table [2](#T2){ref-type="table"}**). Neither the sleep condition (*p* = 0.241; *F* = 1.470) nor the interaction between sleep and sex had a significant impact on cortisol levels (*p* = 0.273; *F* = 1.279; see **Table [2](#T2){ref-type="table"}**).

Effect of TSD on Pain Parameters and Anxiety
--------------------------------------------

The mandatory prerequisite of our study was to induce pain hypersensitivity and increased state anxiety levels by TSD. In accordance with this goal, study subjects developed cold hyperalgesia (CPT, *p* = 0.05), heat hyperalgesia (HPT, *p* = 0.02) and hyperalgesia to pricking pain (logMPT, *p* = 0.013) after TSD, while PPTs were not significantly affected (see **Figure [2](#F2){ref-type="fig"}** and the column "sleep" of **Table [2](#T2){ref-type="table"}**). **Table [3](#T3){ref-type="table"}** shows that the effect sizes related to this study population are similar to those of our previously published larger study group, of which our study participants represent a subgroup \[see ([@B22])\]. We found a significant sex ^∗^ sleep condition interaction with respect to HPT and logMPT, with females becoming more sensitive to heat (*p* = 0.036) and males becoming more sensitive to pricking pain (*p* = 0.040) (see **Table [2](#T2){ref-type="table"}** and **Figure [2](#F2){ref-type="fig"}**). Like previously shown ([@B22]), the effect of TSD on descending pain inhibition, represented by the parameter "PPT~prae-post~," did strongly depend on sex (sex ^∗^ sleep interaction: *p* = 0.013). In females, descending pain inhibition was strongly impaired after TSD (*p* = 0.008). On the contrary, the capacity to inhibit pain tended to be even stronger after TSD in the male study population (*p* = 0.21). Results are depicted in **Figure [3](#F3){ref-type="fig"}** and RM-ANOVA analysis is given in **Table [2](#T2){ref-type="table"}**.

![Effect of sleep deprivation on nociceptive thresholds. The figures depict raw data of quantitative sensory testing, based on the mixed gender population. There was a main effect of the sleep condition on thermal pain sensitivity (CPT, HPT). With respect to mechanical submodalities, the sensitivity to pricking stimuli (MPT), but not to blunt pressure (PPT), was significantly increased. ^∗^*p* \< 0.05; data are given as mean ± SEM.](fnbeh-12-00161-g002){#F2}

###### 

Effect sizes.

                          Cohen's *d*   *p*       Cohen's *d*   *p*
  ----------------------- ------------- --------- ------------- ---------
  CPT                     -0.469        0.050     -0.731        \<0.001
  HPT                     0.505         0.023     0.626         \<0.001
  logPPT                  0.374         0.11      0.343         0.049
  logMPT                  0.560         0.013     0.541         0.002
  STAI-State              -1.052        \<0.001   -0.937        \<0.001
  PPT~prae-post~ total    -0.065        0.739     -0.021        0.670
  PPT~prae-post~ female   -0.760        0.008     -0.381        0.023
  PPT~prae-post~ male     0.301         0.210     0.115         0.480
                                                                

The columns two and three depict effect sizes and

p

-values for TSD-induced changes of outcome parameters in our study population of

n

= 20 study participants. Data from columns four and five refer to the recently published larger data set of

n

= 36 study participants (

Eichhorn et al., 2017

). Apart from logPPT, which failed to be significant in our smaller data set (

p

= 0.11); results are comparable with each other. CPT, cold pain threshold; HPT, heat pain threshold; PPT, pressure pain threshold; MPT, mechanical pain threshold; STAI-State, state anxiety inventory.

![Effect of sleep deprivation on descending pain inhibition. **(A)** The females' capacity to inhibit pain was significantly decreased after TSD, while males tended to exhibit stronger pain inhibition. **(B)** Consequently, the effect of TSD on the entire study population was not significant. Solid line brackets below vertical bars indicate results from paired *t*-tests, while the dashed bracket in **(A)** relates to the significant sleep ^∗^ sex interaction (RM-ANOVA). ^∗∗^*p* \< 0.01; data are given as mean ± SEM.](fnbeh-12-00161-g003){#F3}

### State Anxiety

Anxiety levels, assessed by the STAI-State Inventory, increased significantly after sleep deprivation (HS: 28.0 ± 0.9; TSD: 33.1 ± 1.2; *p* = \< 0.001). This effect was independent of gender (RM-ANOVA: sleep ^∗^ sex interaction, *p* = 0.429; see **Table [2](#T2){ref-type="table"}**). **Figure [4](#F4){ref-type="fig"}** depicts results both separated by sex and based on the mixed gender population.

![Effect of sleep deprivation on anxiety levels. **(A)** The significant effect of TSD on State Anxiety was prominent in both females and males, and consequently in the entire study population **(B)**. Accordingly, there was no significant sleep ^∗^ sex interaction. Solid line brackets are related to paired *t*-tests. Dashed line brackets relate to the sex ^∗^ sleep interaction (RM-ANOVA). ^∗∗^*p* \< 0.01; ^∗^*p* \< 0.05; data are given as mean ± SEM.](fnbeh-12-00161-g004){#F4}

Correlation Analyses and Hierarchical Regression Analyses
---------------------------------------------------------

### Correlation Between OT and Nocicepive Thresholds

Oxytocin-levels neither correlated with CPTs nor with Pressure Pain or MPTs (see **Table [4](#T4){ref-type="table"}**). However, based on the entire study population, we found a significant correlation between plasma OT-levels and HPTs. Higher OT levels were associated with a stronger sensitivity to noxious heat (*r* = -0.333; *r*^2^ = 0.111; *p* = 0.036, **Figure [5C](#F5){ref-type="fig"}** and **Table [4](#T4){ref-type="table"}**). When separating results by sex, bivariate correlations were not significant (females: *p* = 0.143 and males: *p* = 0.547; see **Figures [5A,B](#F5){ref-type="fig"}** and **Table [4](#T4){ref-type="table"}**). Accordingly, neither adding the variable 'sex' (0.3% increase of explained variance) nor 'sleep' (3.1% increase of explained variance) to a model of hierarchical regression analysis resulted in reinforcement of the result, thus indicating that none of these two variables is of further predictive value (**Table [5A](#T5A){ref-type="table"}**).

###### 

Correlations between OT levels and outcome parameters.

                         Mixed sex   Female      Male                                                   
  ---------------------- ----------- ----------- ------- -------- ----------- -------- -------- ------- -------
  CPT                    0.007       0.965       0.002   0.128    0.592       0.298    0.067    0.777   0.083
  HPT                    -0.333      **0.036**   4.748   -0.339   0.143       2.342    -0.143   0.547   0.376
  PPT                    0.243       0.130       2.392   0.023    0.924       0.009    0.027    0.925   0.009
  MPT                    0.236       0.142       2.245   0.375    0.104       2.938    0.143    0.548   0.376
  Ratio PPT~prae-post~   0.186       0.251       1.359   0.386    **0.093**   3.149    0.340    0.143   2.347
  STAI                   0.363       **0.021**   5.766   0.650    **0.002**   13.135   0.087    0.717   0.136
  Cortisol               0.031       **0.897**   0.017   0.821    **0.004**   16.487   0.385    0.271   0.149
                                                                                                        

This table depicts the correlation coefficient (

r

) between the respective outcome parameter and the oxytocin concentration of study participants. Results are given for both the mixed gender population and for the female and male subpopulation. CPT, cold pain threshold; HPT, heat pain threshold; PPT, pressure pain threshold; MPT, mechanical pain threshold; MPS, mechanical pain sensitivity. The ratio PPT

post/prae

enables to estimate whether the exposition to ice cold water resulted in pain inhibition (value \> 1.0) or facilitation (value \< 1.0). STAI, State Anxiety Score of the STAI-Inventory. Values marked in bold indicate significancy of results.

![Correlation between OT and HPT. The mild association between heat pain thresholds and plasma-OT concentrations was only significant on the basis of the sex-mixed study population \[*p* = 0.036, **(C)**\], but not when separately analysing data from females **(A)** or males **(B)**. The variable "sex" did not significantly account for the correlation between HPT and OT-levels.](fnbeh-12-00161-g005){#F5}

###### 

Hierarchical Regression Model: Correlation between HPT and Oxytocin.

  HPT             Full model   Sex        Sleep      Oxy                                                                         
  --------------- ------------ ---------- ---------- ------- ------- ------- ------- -------- -------- ------- -------- -------- --------
  Oxy             4.744        0.036^b^   0.333^a^   0.111                                                     -0.333   -2.178   -0.036
  Oxy sex         2.383        0.106^c^   0.338^b^   0.114   0.067   0.361   0.720                             -0.296   -1.597   0.119
  Oxy sex sleep   2.031        0.127^d^   0.380^c^   0.145   0.096   0.515   0.610   -0.180   -1.135   0.264   -0.244   -1.279   0.209
                                                                                                                                 

Oxytocin and HPT are significantly correlated (

p

= 0.036). However, the predictive power is only marginally increased when adding "sex" (0.3% increase) or "sleep" (3.1%) to the model.

### Correlation Between OT and Descending Pain Inhibition

On the basis of the mixed sex population, the capacity to inhibit pain was not correlated with OT-levels (*p* = 0.251, see **Table [4](#T4){ref-type="table"}** and **Figure [6C](#F6){ref-type="fig"}**). Contrary to males (see **Figure [6B](#F6){ref-type="fig"}** and **Table [4](#T4){ref-type="table"}**), there was a mild tendency of less pain inhibition being associated with higher OT levels (*r* = 0.386, *p* = 0.093; **Figure [6A](#F6){ref-type="fig"}** and **Table [4](#T4){ref-type="table"}**).

![Correlation between OT and descending pain inhibition. Separated by sex, plasma OT-levels of females \[**(A)**, *p* = 0.093\], but not males **(B)**, tended to be higher in those subjects who had a lower capacity to inhibit pain \[*p* = 0.093, **(A)**\]. Values below the dashed line indicate pain inhibition while values above the line indicate pain facilitation due to ice cold water exposition. Based on the sex-mixed population, results were not significant **(C)**.](fnbeh-12-00161-g006){#F6}

### Correlation Between OT and STAI

Based on the sex-mixed population, the correlation between anxiety levels and OT concentrations was significant (*r* = 0.363; *r*^2^ = 0.132; *p* = 0.021; **Figure [7C](#F7){ref-type="fig"}**). When separating results by sex, a strong association between OT concentrations and STAI-scores was only found in females (*r* = 0.650; *p* = 0.002; **Figure [7A](#F7){ref-type="fig"}**), not males (*r* = 0.087; *p* = 0.717, **Figure [7B](#F7){ref-type="fig"}**). Conducting a hierarchical regression analysis, the predictive power of OT (∼13.2% of explained variance) was further increased when adding the variables "sex" (*r*^2^ = 0.229; *p* = 0.008) and "sleep" (*r*^2^ = 0.371; *p* = 0.001) to the model (see **Table [5B](#T5B){ref-type="table"}**).

![Correlation between OT-levels and state anxiety. Only the state anxiety scores of females are correlated with increased OT-levels \[*p* = 0.002, see **(A)**\]. In males, the anxiogenic effect of TSD does not seem to be related to the oxytocin level (*p* = 0.717, see **B**\]. Based on the entire study population **(C)**, results are still significant (*p* = 0.021).](fnbeh-12-00161-g007){#F7}

###### 

Hierarchical Regression Model: correlation between STAI and oxytocin.

  STAI            Full model   Sex     Sleep   Oxy                                                                     
  --------------- ------------ ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- -------
  Oxy             5.766        0.021   0.363   0.132                                                   0.363   2.401   0.021
  Oxy sex         5.508        0.008   0.479   0.229   0.375   2.166   0.037                           0.569   3.292   0.002
  Oxy sex sleep   7.084        0.001   0.609   0.371   0.312   1.951   0.059   0.388   2.849   0.007   0.456   2.791   0.008
                                                                                                                       

Oxytocin accounts for 13.2% of variability regarding STAI-scores (13.2%.

p

= 0.021). This significant result is further increased to

p

= 0.008 by adding "sex" to the model. Entering the variable "sleep" to the model explains another 14.2% of variance. Since at this point the significance level of the variable "sex" decreases to 0.059, the overlapping effect of "sex" and "sleep" seems to be stronger carried by "sleep" than "sex."

Correlation Between Cortisol and OT
-----------------------------------

Based on the entire study population, OT and cortisol were not significantly correlated with each other (*p* = 0.734, see **Table [5C](#T5C){ref-type="table"}**). Only when entering the variable "sex" to the hierarchical regression analysis, the predictive power is significantly increased (full model: *p* = 0.027). Adding the 'sleep condition' does only explain another 1.0% of variance and reduces the significance just below the significance level (*p* = 0.056).

###### 

Hierarchical Regression Model: correlation between salivary cortisol and oxytocin.

  Cortisol        Full model   Sex     Sleep   Oxy                                                                           
  --------------- ------------ ------- ------- ------- -------- -------- ------- -------- -------- ------- -------- -------- -------
  Oxy             0.117        0.734   0.055   0.003                                                       0.055    0.342    0.734
  Oxy sex         3.977        0.027   0.421   0.177   -0.500   -2.796   0.008                             -0.220   -1.232   0.226
  Oxy sex sleep   2.760        0.056   0.432   0.187   -0.483   -2.657   0.012   -0.103   -0.668   0.508   -0.190   -1.023   0.313
                                                                                                                             

While absolute values of cortisol and oxytocin do not correlate with each other, entering the variable "sex" to the model is able to increase the predictive power by 17.4%. Adding the variable "sleep" to the model does only explain another 1.0% of variance in the full model. This finding indicates that our finding is mainly carried by sex.

Discussion
==========

Effect of TSD on Plasma OT Levels
---------------------------------

We found a sex-dependent effect of TSD on the plasma OT-concentration of study participants. To our knowledge, human studies on the contribution of OT to the pathophysiology of sleep disruption are lacking so far. Only two rodent studies have been published on this topic. Results of these studies, however, were contradictory. Fujihara and co-authors ([@B25]) were unable to demonstrate significant changes of OT mRNA-levels in hypothalamic nuclei of *male* rats when using a short-term (6 h) paradigm of selective REM-sleep deprivation. On the contrary, [@B60] observed an increase of plasma OT-levels in sleep restricted *pregnant rats*, who underwent a long-term paradigm of cumulative sleep restriction (20 h/daily) over six days. Study inconsistencies may not only be explained by methodological differences (regarding, for example, the sleep restriction model or the choice of outcome parameters) but also by differences regarding sex and the hormonal state of the study animals. In our human study, sex revealed to have a crucial impact on study results since plasma levels of OT did only increase in sleep deprived females, not males. However, due to the fact that all female study participants were taking monophasic contraceptives, our findings may not hold true for naturally cycling women. In addition to the fact that *endogenous* estrogens are capable to profoundly activate OT synthesis and release ([@B63]; [@B1]), exogenous estrogens (derived from OC) have been shown to increase plasma OT-levels ([@B80]; [@B16]; [@B72]). Based on this knowledge, the intake of ethinylestradiol may have had a significant impact on our study results. In order to evaluate the particular contribution of OC to sleep deprivation effects, future sleep deprivation studies thus need to specifically compare naturally cycling females with females taking OC.

Correlation Between Plasma OT Levels and Pain Thresholds
--------------------------------------------------------

Using correlation analyses, our study failed to show a significant association between plasma OT concentrations and cold pain, pricking, or pressure pain. Regarding cold pain, our negative finding is in accordance with Grewen and co-authors ([@B31]), who were hardly able to show an association between plasma OT and the tolerance to noxious cold when respecting the factor 'ethnicity' in their analysis. In contrast to our methodological approach, two other studies used exogenously applied OT to explore its effect on cold pain. Results, however, were contradictory. While Zunhammer and co-authors ([@B98]) were unable to demonstrate a significant effect of intranasal OT on CPTs, [@B66] reported a significant increase of CPTs and a decrease of perceived cold pain intensity/unpleasantness after administration of OT. Altogether, at least these studies on the correlation between *endogenous* OT and evoked cold pain failed to support the hypothesis of plasma OT being predictive for cold pain sensitivity in humans.

In contrast to cold pain, we found a significant -- but sex and sleep-independent -- correlation between plasma OT levels and HPTs. This finding indicates that -- contrary to what we expected -- *sleep deprivation* does not play a decisive role in the correlation between plasma OT-levels and HPTs. The previous investigations on the impact of OT on heat pain were highly equivocal. Both attenuation ([@B98]; [@B59]) and enhancement of perceived heat pain intensity ([@B88]) have been reported, but a lack of effect has also been observed ([@B31]; [@B38]; [@B23]; [@B97]). Compared to psychophysical studies, Paloyelis and co-authors used laser-heat evoked potentials (LEP) to explore the effect of intranasal OT on heat pain in healthy males. They found that OT was not only able to attenuate subjective pain ratings but to also reduce the amplitudes of the N1 and the N2-component of LEP's. LEP's represent an objective measure of nociceptive processing and reflect the cortical response to noxious radiant heat. Thus, in some agreement with our own finding, the LEP-study provides with some objective electrophysiological evidence for an involvement of OT in heat pain perception.

We failed to show an association between the perception of noxious mechanical stimuli and plasma OT-levels. The previous studies on a modulatory role of the OT-system for pricking and pressure pain are lacking. In fact, except for thermal pain perception, knowledge on the effect of OT on other nociceptive modalities like visceral pressure pain ([@B45]) or electrical pain ([@B81]) relies on single study observations. Thus, we are currently unable to seriously discuss the role of OT for mechanical pain perception in this study. Furthermore, studies, which address the impact of OT on the entire spectrum of the nociceptive system, are needed to advance our understanding of the contribution of OT for the perception of different nociceptive modalities.

Descending Pain Inhibition
--------------------------

In accordance with our previously published results on sex-dependent effects of TSD on descending pain inhibition, only sleep-deprived female OC-users showed impairment of their endogenous pain control ([@B22]). Accordingly, we found a sex-dependent (but insignificant) correlation between pain inhibition and OT. While, in females, higher plasma OT-concentrations showed -- by tendency -- an association with lower capacities to inhibit pain, a similar effect in males was lacking.

So far, only one previous study focused on the impact of OT on endogenous pain control. In this study, intranasally applied OT had a significant effect on descending pain control. This effect, however, was dependent on the site at which the outcome parameter was measured. While OT did not modulate conditioned pressure pain measured at the forearm, enhanced pain inhibition was observed at the masseter muscle ([@B30]). Though the authors argue that the route of OT administration (intranasally) may have resulted in a preferred effect of the neuropeptide on the trigeminally innervated anatomical site, the site-specific aspect of this study nevertheless remains elusive. Unfortunately, apart from the study performed by Goodin et al., human studies on the correlation between OT and the endogenous capacity to inhibit pain are currently missing. Thus, in view of our currently sparse and heterogeneous data, we strongly support to continue human research on the modulatory effect of OT on supraspinal pain control in humans.

OT and Anxiety
--------------

Contrary to its minor contribution to TSD-induced effects on experimental pain, OT had a considerable predictive power regarding state anxiety. This finding is in line with a large body of evidence for an important role of the OT-system for anxiety and fear ([@B35]; [@B47]; [@B21]; [@B33]). Notably, sex revealed to play an important role in our study. Similar sex-dependent effects have been observed by Weisman and co-authors, who explored the correlation between Trait Anxiety-scores and plasma OT-concentrations. According to their finding, males showed an inverse correlation between plasma OT-levels and Trait Anxiety scores, while a subgroup of females with particular high anxiety scores exhibited the reverse -- i.e., a positive correlation ([@B89]). Opposing findings have also been observed in other neurophysiological domains of anxiety. In males, higher plasma OT-levels correlated with lower "attachment anxiety," while the reverse was observed in females ([@B50]; [@B89]). Unfortunately, none of these studies controlled for the use of OC. Thus, we are not able to further discuss putative differences between naturally cycling females and OC-users. An OC-independent role of female sex has, however, been shown in a study from our team, where we demonstrated that OT plays a key role in attenuation of anxiety during lactation -- a physiological state known to drastically boost the OT-system ([@B54]). Altogether, in light of our currently limited knowledge, it becomes obvious that future studies urgently need to take the putative impact of OC's into account. By contrasting naturally cycling females with female OC-users and with males, we will be able to more specifically determine the probable sex-dependent role of OT for modulating anxiety.

OT and Cortisol
---------------

Irrespective of the sleep condition, females showed higher basal cortisol levels than males. This may be due to hormonal bias by OC since -- independent of the menstrual cycle -- elevated plasma cortisol levels have been observed in females taking OC when compared to those using natural contraception methods ([@B39]; [@B52]).

According to our findings, cortisol levels of sleep deprived study participants did not significantly increase. Animal experiments on the cortisol response to sleep loss indicate that activation of the HPA-axis depends on the duration and the model of sleep deprivation ([@B53]; [@B25]; [@B92]). Accordingly, our short-term protocol of sleep deprivation may, on average, have been only a mild stressor -- at least from the perspective of young healthy medical students. Since OT is discussed to be dynamically interrelated with cortisol ([@B35]; [@B15]; [@B12]), we finally aimed to assess the association between these two stress-related biomarkers at the individual level. Based on the sex-mixed study population, we were not able to show a significant correlation between OT and cortisol. However, "sex" revealed to play a significant role since the predictive power of OT increased markedly when respecting 'sex' in a hierarchical regression analysis. In the literature, OT is discussed to buffer the cortisol response to stress. Results, however, have been equivocal and neither sex differences nor the impact of OC have been specifically addressed so far ([@B15]; [@B12]; [@B52]). Therefore, we strongly suggest performing the future studies in order to explore the impact of endogenous and exogenous sex hormones on the putative cortisol buffering effect of OT.

### Methodological Considerations

We applied rigid inclusion/exclusion criteria and used highly standardized procedures to minimize confounding factors. By double-monitoring of study participants during the sleep deprivation night, via an Actiwatch Device and a student assistant, TSD was ensured. Apart from the fact that, inherent to the study design, the significance of our data may not be extrapolated to naturally cycling women, several drawbacks of the study need to be discussed.

1.  An important methodological limitation of our study relates to the fact that our model is not able to induce spontaneous pain. Thus, our analyses had to be restricted to study correlations between plasma OT and evoked pain. Another drawback relates to exclusively focusing on "anxiety" as an affective outcome measure. Contrary to the previous studies ([@B30]; [@B98]; [@B97]), our study did not include other parameters like the "Profile of Mood States" (POMS) or an "Unpleasantness-scale" to further evaluate the role of OT regarding the affective domain. Consequently, apart from "anxiety," we are not able to further comment on the impact of OT on the emotional aspects of pain in our sleep deprivation model.

2.  Our study did not integrate a night of "restorative sleep" in order to show the reversibility of our finding. Future studies, thus should extend the study protocol and include repetition of experiments under the condition 'restorative sleep'. This approach will help to further strengthen the significance of the presented study findings.

3.  Finally, we assessed OT in the blood, but not in the cerebrospinal fluid. Although this approach is common ([@B3]; [@B2]; [@B31]), uncertainty remains whether plasma OT can be regarded an adequate outcome parameter for studying causal relations between OT effects and specific behavioral patterns ([@B37]). However, although the cerebrospinal fluid space would have been the preferred target compartment in our study, ethical reasons prevented us from collecting CSF in healthy study participants.

Conclusion
==========

Our findings suggest that sleep-deprivation related changes of OT are not causally linked to TSD-induced thermal and mechanical hyperalgesia. In addition, OT may only play a minor role for impaired descending pain inhibition of sleep deprived females. In contrast to its neglectable contribution to altered pain thresholds, OT appears to be particularly involved in females' increased anxiety-levels. This discrepancy suggests that TSD induced effects on anxious mood and experimental pain are -- at least with respect to the biomarker OT -- differentially regulated. Notably, the significance of our data relates to females using OC's. In addition, our study population was investigated under artificial experimental conditions. We strongly suggest re-investigating the role of OT in a patient cohort since our experimental findings still do not exclude that OT may contribute to the perceived intensity of spontaneous pain in chronic pain patients suffering from sleep disturbances.
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BDI

:   beck depression inventory

CDT

:   cold detection threshold

CPM

:   conditioned pain modulation

CPT

:   cold pain threshold

DMA

:   dynamic mechanical allodynia

HPT

:   heat pain threshold

ICHD

:   international headache classification

MDT

:   mechanical detection threshold

MPT

:   mechanical pain threshold

OT

:   oxytocin

PPT

:   pressure pain threshold

PSQI

:   Pittsburgh sleep quality index

QST

:   quantitative sensory testing

SD

:   standard deviation

SEM

:   standard error of the mean

STAI

:   state and trait anxiety inventory

TSD

:   total sleep deprivation
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